Neutral
Sarepta, Amylyx and Neumora look ahead to key catalysts as Q1 earnings roll in
As Q1 earnings approach, Sarepta, Amylyx, and Neumora Therapeutics are facing pivotal moments tied to key catalysts. Sarepta anticipates important rea...